Chemistry.AI is a platform described for medicinal chemists to evaluate molecular classes and measure brain activity and physiological responses during exposure to molecules, with aims to assess whether a medicinal chemist can sense good versus bad molecules and distinguish human-designed molecules from those generated by artificial intelligence. The project discusses leveraging medicinal chemistry expertise to train and evaluate deep neural networks, and to explore the role of top-performing chemists as discriminators in AI training for pharma applications. It situates itself within the pharmaceutical research landscape, touching on drug discovery and clinical trial prediction concepts, and is associated with Insilico Medicine. The content references operations in Hong Kong and ongoing development across the biomedical AI space.
Does DEI Still Have a Role to Play in Employer Branding?
Leap Cofounder’s New Venture Noon Raises $44 Mn To Scale AI-Native Product Design Tool
Yuzu Health Raises $35M to Modernize Health Insurance TPA Infrastructure
EXCLUSIVE: Ex-A16z Partner Michelle Volz Launches Pax Ventures with $50 Million First Fund to Bet on 'Industrial-Scale Markets'